Primorigen Biosciences, Inc.

Madison, WI 53719

SBIR Award Summary

Total Number of Awards 21
Total Value of Awards $7.22MM
First Award Date 09/01/08
Most Recent Award Date 04/01/15

Key Personnel

Last Name Name Awards Contact
Monsma Scott Allen Monsma 14
Garcia Bradley H. Garcia 3
Lee Jae-Sung Lee 5

21 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 04/01/15 - 03/31/16

DESCRIPTION (provided by applicant): Primorigen Biosciences SBIR Proposal Abstract Primorigen Biosciences will develop a defined, xenobiotic-free synthetic cell culture matrix that fully supports maintenance and directed differentiation of human induced pluripotent stem cells (hiPSCs) down all three germ layers and dramatically reduces the costs...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 04/01/15 - 03/31/16

DESCRIPTION (provided by applicant): Primorigen Biosciences(R) Project Abstract Primorigen will use SBIR funds to develop a paradigm-changing technology for expansion and directed differentiation of human pluripotent stem cells (hPSCs) using a novel peptide that dramatically reduces costs by amplifying the impact of endogenous growth factors and...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-122
Budget: 08/31/14 - 08/30/15

DESCRIPTION (provided by applicant): Primorigen will use SBIR SHIFT funds to develop an array system that can identify chemically-defined surfaces to optimize induced pluripotent stem cell (hiPSC) differentiation and maturation. The platform initially will be validated for its capacty to help increase functional maturity of stem cell-derived hep...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 04/01/14 - 03/31/15

DESCRIPTION (provided by applicant): Primorigen Biosciences(R) Project Abstract Primorigen will use SBIR funds to develop a paradigm-changing technology for expansion and directed differentiation of human pluripotent stem cells (hPSCs) using a novel peptide that dramatically reduces costs by amplifying the impact of endogenous growth factors and...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 03/01/14 - 02/28/15

DESCRIPTION (provided by applicant): Primorigen Biosciences (R) Abstract Primorigen Biosciences will use Phase II SBIR funds to advance its novel, 3-dimensional system for robust expansion of induced pluripotent stem cells (iPSCs) by a) scaling up iPSC production in 3L bioreactors, b) validating the bioreactor-expanded iPSCs for differentiatatio...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-122
Budget: 09/30/13 - 09/29/14

DESCRIPTION (provided by applicant): Primorigen will use SBIR SHIFT funds to develop an array system that can identify chemically-defined surfaces to optimize induced pluripotent stem cell (hiPSC) differentiation and maturation. The platform initially will be validated for its capacty to help increase functional maturity of stem cell-derived hep...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-ES-13-003
Budget: 09/15/13 - 08/31/14

Primorigen Biosciences (R) Abstract Primorigen Biosciences will use SBIR funds to develop a novel commercial assay that measures the toxicity of compounds on human induced pluripotent stem cells (hiPSCs) differentiating into hematopoietic progenitor cells (HPCs) and on HPCs differentiated from hiPSCs. The assay will rely on Primorigen's highly e...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-ES-13-003
Budget: 09/01/13 - 08/31/14

Primorigen Biosciences (R) Abstract Primorigen Biosciences will use SBIR funds to develop a high-throughput toxicology assay system utilizing human ventricular cardiomyocytes (vCMs) differentiated from human induced pluripotent stem cells (hiPSCs). Phase I studies will convert the small-molecule based, cytokine-free CardioTotal" differentiation ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-451
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): Primorigen Biosciences will use Phase II SBIR funds to accelerate and expand the development of new regenerative medicine cell therapies by developing a novel high throughput, low cost protein quantification system for characterizing pancreatic 2 cell and islet cell differentiation. Primorigen successfully co...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/01/12 - 07/31/13

DESCRIPTION (provided by applicant): Primorigen Biosciences SBIR Proposal Abstract Primorigen Biosciences will use SBIR funds to develop an advanced cell culturing methodology to increase the efficiency of directed differentiation and to boost functional maturity of induced pluripotent stem cell-derived hepatocytes. The new technology uses propr...

Load More